Cerebral Palsy

01Pathophysiology

Cerebral palsy (CP) is defined as a non-progressive disorder of movement and posture caused by a static lesion or injury to the immature, developing brain. The word "non-progressive" is one of the most tested concepts: the brain lesion itself does not worsen over time, but the clinical manifestations can evolve as the child grows and the nervous system matures. This distinction is critical because if a vignette describes a child whose neurological function is actively deteriorating, you must consider a neurodegenerative condition instead of CP.

The timing of injury determines the pattern of brain damage and, consequently, the clinical subtype. In preterm infants, the most vulnerable brain region is the periventricular white matter, which carries the descending corticospinal fibers for the lower extremities. Damage here, called periventricular leukomalacia (PVL), preferentially affects the leg motor fibers, producing the classic pattern of spastic diplegia (legs more affected than arms). This is why prematurity is so tightly linked to the diplegic pattern, and why PVL on MRI in the setting of a former premature infant with bilateral lower extremity spasticity is a textbook combination.

In term infants, the most metabolically active regions of the brain are the basal ganglia, thalamus, and the parasagittal cortex. Hypoxic-ischemic injury at term therefore tends to damage these deeper gray matter structures, leading to either spastic quadriplegia (if the cortex and deep structures are widely involved) or dyskinetic (athetoid/choreoathetoid) CP (if the basal ganglia bear the brunt of injury). Kernicterus from severe unconjugated hyperbilirubinemia is another classic cause of basal ganglia injury and dyskinetic CP; this association remains high-yield even though exchange transfusions have made it rare.

The upper motor neuron (UMN) pathway is almost always involved in the spastic forms, which account for roughly 70-80% of all CP. Damage to the corticospinal tract produces the familiar UMN constellation: spasticity, hyperreflexia, clonus, a positive Babinski sign, and scissoring gait. Understanding that CP is an UMN disease helps you quickly differentiate it from lower motor neuron conditions (such as spinal muscular atrophy) that present with hypotonia and absent reflexes.

A key pathophysiological point for the exam: the motor deficit is the defining feature of CP, but most children with CP also have associated comorbidities including intellectual disability (about 50%), epilepsy (25-45%), visual impairment, hearing loss, speech and language disorders, and behavioral problems. The vignette may focus on one of these comorbidities, but the underlying diagnosis is still CP.

02Classification and Clinical Manifestation

By Motor Type

By Topography

By Functional Severity (Gross Motor Function Classification System, GMFCS)

The GMFCS is testable because it guides prognosis and treatment planning. A child classified as GMFCS Level I has a very different rehabilitation plan and surgical candidacy compared to GMFCS Level V.

03Diagnostic Workup

The diagnosis of cerebral palsy is clinical. There is no single laboratory test, imaging study, or biomarker that "confirms" CP. The diagnosis rests on recognizing a child with a non-progressive motor disorder that originated from injury to the developing brain, combined with the characteristic physical exam findings.

The best initial step in evaluating a child with suspected CP is a thorough developmental and neurological examination. You are looking for delayed motor milestones (the child who is not sitting unsupported by 9 months, not walking by 15-18 months), abnormal muscle tone (most commonly increased tone with spasticity, but hypotonia can be the initial presentation in young infants before spasticity develops), persistent primitive reflexes (such as the Moro reflex persisting beyond 6 months or the asymmetric tonic neck reflex persisting beyond 6-7 months), and early hand dominance before 12 months (a red flag for hemiplegia, since children normally do not establish handedness until 18-24 months).

Brain MRI is the most informative neuroimaging study and should be obtained in virtually all children with suspected CP. MRI is abnormal in approximately 80-90% of cases and helps establish the etiology and timing of the brain injury. In former preterm infants, the hallmark finding is periventricular leukomalacia, visible as white matter volume loss and signal abnormality around the lateral ventricles. In term infants with a history of perinatal asphyxia, you will see basal ganglia and thalamic signal abnormality. In children with spastic hemiplegia, MRI may reveal a focal infarct in the territory of the middle cerebral artery. A normal MRI does not exclude the diagnosis but should prompt careful reconsideration and further workup for mimics.

Metabolic and genetic testing is not routinely performed when the clinical picture is straightforward and the MRI shows a pattern consistent with CP. However, if the MRI is normal, if the history lacks clear risk factors, or if there are atypical features (such as progressive neurological decline, family history of similar disease, or episodic worsening), you must investigate for metabolic disorders (e.g., glutaric aciduria type I, which mimics dyskinetic CP), genetic conditions (e.g., hereditary spastic paraplegia, dopa-responsive dystonia), and structural brain malformations. This is a frequently tested concept: the exam wants you to know when CP is not CP.

04Management and Treatment

Rehabilitation therapy is the foundation of CP management at every level of severity. Physical therapy aims to maintain range of motion, prevent contractures, strengthen functional muscles, and optimize gait. Occupational therapy targets fine motor skills, feeding, dressing, and adaptive equipment use. Speech-language therapy addresses both communication (many children benefit from augmentative and alternative communication devices) and swallowing safety. These therapies should begin as early as possible and continue throughout childhood.

For spasticity management, the approach is stepwise. The first-line pharmacological option for generalized spasticity is oral baclofen, a GABA-B receptor agonist that reduces spasticity at the spinal cord level. It is started at a low dose (5 mg two to three times daily) and titrated gradually. Sedation, weakness, and lowered seizure threshold are notable side effects. Diazepam (a GABA-A agonist) is an alternative, but its use is limited by sedation, tolerance, and risk of dependence.

For focal spasticity (e.g., isolated equinus due to calf spasticity, or wrist flexor spasticity), the treatment of choice is botulinum toxin A injection into the affected muscles. The toxin blocks acetylcholine release at the neuromuscular junction, producing a temporary, localized reduction in tone lasting 3-6 months. This allows a window for intensive therapy and functional gains. Repeat injections are often needed but must be spaced appropriately to avoid antibody formation.

For severe, generalized, refractory spasticity, the next step is an intrathecal baclofen pump. This delivers baclofen directly into the cerebrospinal fluid, allowing therapeutic concentrations at the spinal cord with much lower systemic doses and fewer systemic side effects. The exam tests awareness of a critical complication: acute baclofen withdrawal from pump malfunction or catheter issues, which can cause rebound spasticity, hyperthermia, rhabdomyolysis, seizures, and death. This is a medical emergency treated with high-dose oral or enteral baclofen and supportive care.

Selective dorsal rhizotomy (SDR) is a neurosurgical procedure reserved for carefully selected children, typically those with spastic diplegia, GMFCS levels II-III, good underlying strength, and no significant dystonia. By selectively cutting sensory nerve rootlets that contribute to the spasticity reflex arc, SDR can permanently reduce spasticity. It is not reversible, and patient selection is critical.

Orthopedic interventions are common and include soft tissue surgery (adductor releases, hamstring lengthening, Achilles tendon lengthening) for dynamic contractures, and bony procedures (femoral and pelvic osteotomies for hip displacement, spinal fusion for scoliosis) for structural deformities. Hip surveillance with serial radiographs is standard of care in children with CP, as the incidence of hip displacement increases with GMFCS level (approaching 90% in GMFCS V).

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get questions about CP wrong is confusing CP with a progressive or degenerative neurological condition. The vignette for CP will never describe worsening brain pathology or loss of previously acquired cognitive milestones. If the stem mentions that the child was "developing normally and then started to lose skills," you are being steered toward a neurodegenerative disease, not CP. The clinical manifestations of CP may change as the child grows (for example, an infant may initially present with hypotonia before spasticity becomes apparent), but this evolution of signs is not the same as disease progression.

A second classic trap involves early hand preference. Normal children do not establish hand dominance until approximately 18-24 months of age. If a vignette describes a 6 or 8-month-old infant who "always reaches with the right hand" or "never uses the left hand," this is not a normal developmental variant. This is a red flag for spastic hemiplegia affecting the contralateral side, and the question is testing whether you recognize this subtle early sign.

Third, remember that a normal MRI does not rule out CP. About 10-15% of children with CP have normal neuroimaging. In such cases, the exam expects you to pursue additional workup for treatable mimics, particularly metabolic and genetic disorders. The core competency being tested is your ability to recognize when the clinical picture does not fully fit CP and to appropriately expand your differential.

Fourth, be aware of the intrathecal baclofen withdrawal scenario. If a vignette presents a child with CP who has an implanted baclofen pump and develops acute onset of worsening spasticity, high fever, and altered mental status, the answer is acute baclofen withdrawal, and it is a medical emergency requiring immediate intervention.

Finally, the exam frequently tests the association between prematurity, periventricular leukomalacia, and spastic diplegia as a linked triad. When you see a former premature infant presenting with bilateral lower extremity spasticity, scissoring gait, and relatively spared upper limbs and cognition, you should recognize spastic diplegia and anticipate PVL on MRI. This pattern is one of the most predictable and testable vignettes in pediatric neurology.